GLUE - Monte Rosa Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

GLUE is currently covered by 2 analysts with an average price target of $16.77. This is a potential upside of $5.63 (50.54%) from yesterday's end of day stock price of $11.14.

Monte Rosa Therapeutics's activity chart (see below) currently has 28 price targets and 27 ratings on display. The stock rating distribution of GLUE is 66.67% HOLD and 33.33% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 70.56% with an average time for these price targets to be met of 347.67 days.

Highest price target for GLUE is $17, Lowest price target is $10, average price target is $13.5.

Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 20-Mar-2025. First documented stock forecast 18-Jul-2021.

Best performing analysts who are covering GLUE - Monte Rosa Therapeutics:

Eric Joseph Robert Driscoll Richard Law Derek Archila Andrew Berens Edward Tenthoff

Currently out of the existing stock ratings of GLUE, 2 are a HOLD (66.67%), 1 are a BUY (33.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$10

$-1.14 (-10.23%)

$11

7 months 5 days ago
(20-Mar-2025)

2/5 (40%)

$4.2 (72.41%)

252

Buy

$17

$5.86 (52.60%)

$11

7 months 5 days ago
(20-Mar-2025)

3/4 (75%)

$11.2 (193.10%)

506

Buy

$16

$4.86 (43.63%)

1 years 3 months 28 days ago
(27-Jun-2024)

1/3 (33.33%)

$12.26 (327.81%)

45

Buy

$10

$-1.14 (-10.23%)

$11

1 years 11 months 17 days ago
(08-Nov-2023)

3/3 (100%)

$6.7 (203.03%)

378

Hold

$11

$-0.14 (-1.26%)

$11

2 years 2 months 15 days ago
(10-Aug-2023)

3/4 (75%)

$4.31 (64.42%)

876

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is GLUE (Monte Rosa Therapeutics) average time for price targets to be met?

On average it took 347.67 days on average for the stock forecasts to be realized with a an average price target met ratio 70.56

Which analyst has the current highest performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

ERIC JOSEPH

Which analyst has the current lower performing score on GLUE (Monte Rosa Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on GLUE (Monte Rosa Therapeutics)?

Eric Joseph works at JPMORGAN and has 8 price targets and 3 ratings on GLUE

Which analyst is the currently most bullish on GLUE (Monte Rosa Therapeutics)?

Andrew Berens with highest potential upside - $10.81

Which analyst is the currently most reserved on GLUE (Monte Rosa Therapeutics)?

Derek Archila with lowest potential downside - -$1.14

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?